DSGN Design Therapeutics, Inc.

NASDAQ
$12.24

Design Therapeutics, Inc. (DSGN) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.38 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.7% since its last earnings release on August 3, 2026.

Design Therapeutics Beat Consensus Estimates
Monday, August 3, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.38)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.93

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Design Therapeutics, Inc.

Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.